Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

lung_ambition_alliance

Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance

September 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharma

Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …

Feature

AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer

September 9, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 6, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit

It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …

News
astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019
Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …

News
astrazeneca-sign

AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk

September 2, 2019
Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …

News
astrazeneca_building_white

AstraZeneca lupus drug makes comeback to meet main goal at Phase 3

August 29, 2019
Research and Development AstraZeneca, Lupus, anifrolumab, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …

News
astrazeneca_building_white

AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer

August 21, 2019
Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …

News
astrazeneca-sign

AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure

August 20, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga

New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …

News
lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial

August 9, 2019
Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma

AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …

News

AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

July 26, 2019
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

July 19, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMAL Therapeutics, Alzheimer's Ebola, Amgen, AstraZeneca, EMA, FDA, Novartis, pharma

On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …

News
astrazeneca_plaque

AstraZeneca to switch entire fleet to electric vehicles by 2030

July 17, 2019
Research and Development AstraZeneca, EV100, electric vehicles, environmentalism, pharma, renewables

AstraZeneca has revealed plans to use only electric vehicles by 2030. In joining the EV100 group, AstraZeneca will transfer the …

News
astrazeneca_building_white

AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes

July 15, 2019
Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga

The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …

News
astrazeneca_plaque

AstraZeneca’s Imfinzi gets orphan drug designation from FDA

July 12, 2019
Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026